Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/106524
Title: Prevalence and clinical impact of recreational drug consumption in people living with HIV on treatment: a cross-sectional study
Author: Garin, N.
Zurita, B.
Velasco Muñoz, César
Keywords: VIH (Virus)
Drogoaddicció
HIV (Viruses)
Drug addiction
Issue Date: 18-Jan-2017
Publisher: BMJ
Abstract: Objectives: Drug interactions, poor adherence to medication and high-risk sexual behaviour may occur in individuals with HIV using recreational drugs. Thus, we aimed to assess the prevalence of recreational drugs use and to explore its clinical impact in HIV patients on treatment. Methods: Observational, cross sectional, study conducted in a 700 bed university hospital, Barcelona, Spain. A total of 208 adults living with HIV on treatment were included. A questionnaire was administered by clinical pharmacists, including evaluation of sociodemographic variables, past 12-month drug consumption, adherence to antiretrovirals (Simplified Medication Adherence Questionnaire) and high-risk sexual behaviour (condomless sex/multiple partners). Additional data were obtained from clinical records. Recreational drug-antiretroviral interactions were checked in reference databases. Prevalence was calculated for 5% precision and 95% CI. Crude and adjusted binary logistic regressions were performed to identify associations between recreational drug use and adherence problems, and between recreational drug use and high-risk sexual behaviour. Results: From the overall sample, 92 participants (44.2%) consumed recreational drugs over the past 1 year. Of these, 44 (48.8%) had used different types of recreational drugs in this period. We detected 11 recreational substances, including sildenafil and nitrites. The most consumed drugs were: cannabis (68.5%), cocaine (45.5%), nitrites (31.5%), sildenafil (28.3) and ecstasy (19.6%). Relevant interactions occurred in 46 (50%) of the individuals consuming drugs. Recreational drug consumption was found to be related to adherence problems with antiretrovirals (OR: 2.51 (95% CI 1.32 to 4.77) p=0.005) and high-risk sexual behaviour (OR: 2.81 (95% CI 1.47 to 5.39) p=0.002). Conclusions: Recreational drugs are frequently used by HIV patients on treatment. Classical drugs and new substances consumed in sexual context are usual. Recreational drug consumption interferes with several clinical outcomes, including potentially relevant interactions between drugs and antiretrovirals, adherence problems and high-risk sexual behaviour. Thus, there is the urgent need of implementing patient-centred care involving recreational drug consumption.
Note: Reproducció del document publicat a: http://dx.doi.org/10.1136/bmjopen-2016-014105
It is part of: BMJ Open, 2017, vol. 7, num. 1, p. e014105
Related resource: http://dx.doi.org/10.1136/bmjopen-2016-014105
URI: http://hdl.handle.net/2445/106524
ISSN: 2044-6055
Appears in Collections:Articles publicats en revistes (ISGlobal)

Files in This Item:
File Description SizeFormat 
garinn2017_2368.pdf864.33 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons